News BioMarin snaps up Alesta's lead asset for $275m BioMarin will acquire Alesta's experimental therapy for rare bone disease hypophosphatasia for up to $490 million.
News Australia first for Hansa’s Idefirix in commercial kidney tr... Hansa has announced that the first commercial patient in Australia has received a living donor kidney transplant following treatment with Idefirix.
News After failure in sickle cell, Fulcrum merges with Slate Following the failure of its sickle cell programme, Fulcrum Therapeutics will merge with Slate Medicines to advance Slate's migraine therapy.
News Sanofi to lay off 229 Blueprint employees, close offices A year after its $9.1bn acquisition of Blueprint Medicines, Sanofi is moving out of Blueprint's Cambridge, MA offices and letting 229 employees go.
News Capricor’s DMD hope still strong, as it shares financials Capricor shares second quarter financials as FDA reconsiders BLA for DMD therapy deramiocel.
News Tauklarify PET approval for Lantheus in AD NFT pathology The FDA approves Lantheus' Tauklarify radiodiagnostic PET to evaluate NFT pathology in Alzheimer's disease.
News ESMO26: Takeda preps filings on CLDN18.2 gastric cancer data Takeda and Innovent's CLDN18.2-targeting ADC, arcotatug tavatecan, will be filed in Japan on the back of positive survival data in gastric cancer.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
